GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » EV-to-EBITDA

Telo Genomics (Telo Genomics) EV-to-EBITDA

: -4.30 (As of Today)
View and export this data going back to 2016. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Telo Genomics's enterprise value is $9.69 Mil. Telo Genomics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.25 Mil. Therefore, Telo Genomics's EV-to-EBITDA for today is -4.30.

The historical rank and industry rank for Telo Genomics's EV-to-EBITDA or its related term are showing as below:

TDSGF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -72.43   Med: 0   Max: 0.09
Current: -4.42

During the past 12 years, the highest EV-to-EBITDA of Telo Genomics was 0.09. The lowest was -72.43. And the median was 0.00.

TDSGF's EV-to-EBITDA is ranked worse than
100% of 120 companies
in the Medical Diagnostics & Research industry
Industry Median: 15.06 vs TDSGF: -4.42

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-18), Telo Genomics's stock price is $0.15. Telo Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.036. Therefore, Telo Genomics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Telo Genomics EV-to-EBITDA Historical Data

The historical data trend for Telo Genomics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.32 -7.85 -20.23 -9.06 -6.58

Telo Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.33 -5.99 -6.58 -5.09 -4.28

Competitive Comparison

For the Diagnostics & Research subindustry, Telo Genomics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics EV-to-EBITDA Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Telo Genomics's EV-to-EBITDA falls into.



Telo Genomics EV-to-EBITDA Calculation

Telo Genomics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=9.687/-2.253
=-4.30

Telo Genomics's current Enterprise Value is $9.69 Mil.
Telo Genomics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telo Genomics  (OTCPK:TDSGF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Telo Genomics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.15/-0.036
=At Loss

Telo Genomics's share price for today is $0.15.
Telo Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.036.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Telo Genomics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Telo Genomics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics (Telo Genomics) Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.